Pulmonx Q1 Revenue Falls 9% to $20.59M, Slightly Beats Estimates; Maintains Full-Year Guidance
Summary
Pulmonx Corporation reported a 9% year-over-year decline in Q1 revenue to $20.59 million, though this slightly exceeded analyst estimates of $20.43 million. The company posted a net loss of $13.65 million and EPS of -$0.33, continuing its trend of unprofitability as noted in its FY2025 results. While gross margin improved, international revenue was impacted by a delay in China registration, and the stock continues to trade near its 52-week low. Pulmonx maintained its full-year 2026 revenue guidance of $90 million to $92 million, indicating no expected change to its outlook, but also no significant recovery.
At the time of this announcement, LUNG was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.7M. The 52-week trading range was $1.13 to $5.46. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.